Safety results of the enzalutamide expanded access program in the United States and Canada for patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel.
Anthony M. Joshua
Consultant or Advisory Role - Astellas Pharma (U)
Neal D. Shore
Consultant or Advisory Role - Astellas Pharma; Medivation
Fred Saad
Consultant or Advisory Role - Astellas Pharma; Medivation
Honoraria - Astellas Pharma
Research Funding - Astellas Pharma; Medivation
Kim N. Chi
Consultant or Advisory Role - Astellas Pharma
Honoraria - Astellas Pharma
Carl A. Olsson
Consultant or Advisory Role - Medivation
Honoraria - Medivation
Research Funding - Astellas Pharma
Other Remuneration - Medivation
Urban Emmenegger
Consultant or Advisory Role - Astellas Pharma
Honoraria - Astellas Pharma
Research Funding - Astellas Pharma
Mark C. Scholz
No relevant relationships to disclose
William R. Berry
No relevant relationships to disclose
Som Mukherjee
Honoraria - Amgen; Astellas Pharma; Janssen
Eric Winquist
No relevant relationships to disclose
Naomi B. Haas
No relevant relationships to disclose
Nahla Hasabou
Employment or Leadership Position - Astellas Pharma
Carl Dmuchowski
Employment or Leadership Position - Astellas Pharma
Frank Perabo
Employment or Leadership Position - Astellas Pharma
Mohammad Hirmand
Employment or Leadership Position - Medivation
Margaret A. Foley
Employment or Leadership Position - Astellas Pharma
Dana E. Rathkopf
Research Funding - Astellas Pharma; Medivation